Johnson & Johnson Deal History & Licensing Activity
Johnson & Johnson is a large pharma headquartered in US. Over the past three years, Johnson & Johnson has been involved in 33 licensing and acquisition transactions, with a primary focus on Gene Therapy (10 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
11
Active Trials
50
Top Modality
Gene Therapy
Focus Area
Oncology
Johnson & Johnson Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Johnson & Johnson in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| bota-vec | MeiraGTx | Gene Therapy | Phase 3 | license | Apr 2026 |
| botaretigene sparoparvovec (bota-vec) | MeiraGTx Holdings plc | Gene Therapy | Phase 3 | acquisition | Apr 2026 |
| Bota-vec | MeiraGTx | Gene Therapy | Phase 3 | acquisition | Apr 2026 |
Johnson & Johnson Pipeline Focus
Therapeutic areas and modalities where Johnson & Johnson is most active based on deal history and clinical trial data.
Therapeutic Areas
Johnson & Johnson Strategic Signals
Key indicators of Johnson & Johnson's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Johnson & Johnson Clinical Pipeline
Johnson & Johnson has 50 active clinical trials across 6 development phases.
23
Not Applicable
9
Unknown
5
Phase 4
7
Phase 1
5
Phase 2
1
Phase 3
See How Your Asset Matches Johnson & Johnson's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
About Johnson & Johnson Licensing & Deal Activity
Johnson & Johnson is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 33 deals over the past three years, Johnson & Johnson ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Johnson & Johnson include Oncology (13 deals and trials), Immunology (8 deals and trials), Ophthalmology (7 deals and trials), and Hematological Malignancies (7 deals and trials). In terms of modality, Johnson & Johnson has shown particular interest in gene therapy, bispecific antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Johnson & Johnson and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Johnson & Johnson's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.